- Home
- PPBT vs KRKR Comparison
PPBT vs KRKR Comparison
Compare PPBT & KRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- KRKR
- Stock Information
- Founded
- PPBT 2010
- KRKR 2010
- Country
- PPBT Israel
- KRKR China
- Employees
- PPBT N/A
- KRKR 301
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- KRKR Business Services
- Sector
- PPBT Health Care
- KRKR Consumer Discretionary
- Exchange
- PPBT Nasdaq
- KRKR Nasdaq
- Market Cap
- PPBT 2.1M
- KRKR 14.5M
- IPO Year
- PPBT N/A
- KRKR 2019
- Fundamental
- Price
- PPBT $0.60
- KRKR $7.68
- Analyst Decision
- PPBT Strong Buy
- KRKR
- Analyst Count
- PPBT 1
- KRKR 0
- Target Price
- PPBT $33.00
- KRKR N/A
- AVG Volume (30 Days)
- PPBT 2.8M
- KRKR 455.2K
- Earning Date
- PPBT 11-14-2025
- KRKR 09-26-2025
- Dividend Yield
- PPBT N/A
- KRKR N/A
- EPS Growth
- PPBT N/A
- KRKR N/A
- EPS
- PPBT N/A
- KRKR N/A
- Revenue
- PPBT N/A
- KRKR $31,657,328.00
- Revenue This Year
- PPBT N/A
- KRKR $182.55
- Revenue Next Year
- PPBT N/A
- KRKR N/A
- P/E Ratio
- PPBT N/A
- KRKR N/A
- Revenue Growth
- PPBT N/A
- KRKR N/A
- 52 Week Low
- PPBT $0.53
- KRKR $2.76
- 52 Week High
- PPBT $13.95
- KRKR $21.36
- Technical
- Relative Strength Index (RSI)
- PPBT 31.95
- KRKR 60.59
- Support Level
- PPBT N/A
- KRKR $6.85
- Resistance Level
- PPBT $2.36
- KRKR $10.69
- Average True Range (ATR)
- PPBT 0.14
- KRKR 1.90
- MACD
- PPBT -0.10
- KRKR 0.23
- Stochastic Oscillator
- PPBT 25.00
- KRKR 19.24
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.